| Date | Title | Description |
| 24.10.2022 | Using Single-Cell DNA Sequencing to Unravel Clonal Heterogeneity & Progression to Richter’s Transformation in CLL, Upcoming Webinar Hosted by Xtalks | The speaker will discuss how single-cell DNA sequencing allowed high-sensitivity detection of driver mutations that bulk next-generation sequencing didn’t call, identifying minute subclones at the time of CLL diagnosis which were dormant fo... |
| 02.11.2021 | Slone Partners Places Nigel Beard Ph.D. as Chief Technology Officer at Encodia | SOUTH RIDING, Va. (PRWEB) November 02, 2021
Slone Partners, a nationwide executive search firm for life sciences, biotechnology, and healthcare companies, has announced the placement of Nigel Beard Ph.D. as Chief Technology Officer (CTO) at... |
| 09.07.2021 | Sequanta and Mission Bio announce strategic partnership | SHANGHAI, July 8, 2021 /PRNewswire/ -- Sequanta Technologies Co., Ltd. ("Sequanta") and Mission Bio. ("Mission Bio") are pleased to announce that they have entered into a strategic partnership, providing high-quality sin... |
| 18.05.2021 | A New Single-Cell Sequencing and Analysis Platform to Accelerate Cell and Gene Therapy Pipelines, Upcoming Webinar Hosted by Xtalks | The speakers will discuss how highly sensitive single-cell DNA sequencing (scDNA-seq) on the Tapestri Platform accelerates CGT workflows.
TORONTO (PRWEB) May 18, 2021
Cell and gene therapies (CGTs) hold promise for the treatment of a variet... |
| 20.04.2021 | Mission Bio Launches Pharma Assay Development Services to Speed Access to New Technologies | |
| 08.04.2021 | Mission Bio Announces Yan Zhang as New CEO | |
| 30.10.2020 | Mission Bio Launches Single-Cell Multi-Omics System for Precision Cancer Therapies | What You Should Know:
– Mission Bio launches industry’s first and only single-cell multi-omics platform, is announcing the launch of its most comprehensive instrument to-date, to save the industry billions of dollars in drug development cos... |
| 14.08.2020 | Mission Bio raises $70M to scale single-cell cancer R&D platform | Mission Bio has raised $70 million to scale up a single-cell multi-omics technology with applications in the development of oncology drugs. The platform, which is in use at companies including Agios, enables researchers to simultaneously de... |
| 14.08.2020 | Mission Bio raises $70M to scale single-cell cancer R&D platform | Mission Bio has raised $70 million to scale up a single-cell multi-omics technology with applications in the development of oncology drugs. The platform, which is in use at companies including Agios, enables researchers to simultaneously de... |
| 13.08.2020 | Mission Bio raises $70 million to help scale its tech for improving the development of targeted cancer therapies | California-based startup Mission Bio has raised a new $70 million Series C funding round, led by Novo Growth and including participation from Soleus Capital and existing investors Mayfield, Cota and Agilent. Mission Bio will use the funding... |
| 13.08.2020 | Mission Bio, a startup using genomics to develop cancer therapeutics, raises $70M | The company's technology is now adopted by half of all cancer centers in the U.S.
For good reason, the world is currently directing all of its attention and resources toward fighting COVID-19. Even with a pandemic raging, though, other heal... |
| 13.08.2020 | Mission Bio Lands $70M to Expand Cancer Therapies With Single-Cell Multi-Omics Platform | What You Should Know:
– Mission Bio raises $70 million in Series C funding led by Novo Growth to accelerate the development of cancer therapies with single-cell multi-omics.
– Mission Bio’s Tapestri Platform, the first single-cell platform ... |
| 13.08.2020 | Mission Bio Raises $70M in Series C Funding | Mission Bio, Inc., a South San Francisco, Calif.-based developer of high-throughput single-cell DNA and multi-omics analysis, raised $70m in Series C financing.
The round, which brought total funding to more than $120m, was led by Novo Grow... |
| 08.11.2019 | Daily funding roundup - November 7th, 2019 | FamePick raised $4.6M; CrowdStreet landed $12M; Healthify and SquareFoot closed $16M
FamePick: FamePick is a platform for business-minded creators. FamePick raised $4.6m in Series A funding. The round was led by InterVest and individuals in... |
| 28.03.2019 | Mission Bio partners with LabCorp to push genomics in drug development | LabCorp participated in Mission Bio's $30M funding round in December
When it comes to precision health, which encompasses the move toward tailored and personalized medicine over a one-size-fits-all approach, with an emphasis or inclusion of... |
| 14.12.2018 | Daily funding roundup - December 14th, 2018 | NuID raised $2.5M; Aiera raised $3.5M; Block Renovations raised $4.5M; Propel raised $12.8M
NuID: NuID is a blockchain cyber security and digital identity startup. NuID has raised $2.5 million in seed funding at a $20 million pre-money valu... |
| 14.12.2018 | Mission Bio raises $30M in Series B round to develop genomics platform | The purpose of the latest round of funding is to expand the company’s single-cell DNA sequencing platform, Tapestri, into CRISPR applications and move into global markets. Tapestri was launched in October 2017 and has been adopted by more t... |
| 14.12.2018 | Term Sheet — Friday, December 14 | THE RISE OF THE FAMILY OFFICE
While no one was looking, family offices have transformed into financial titans.
Paid Content You can't secure what you can't see From ExtraHop
Family offices control $4 trillion of assets, which is more than h... |
| 13.12.2018 | Companies tracking mutations in cancer cells can provide a key to unlocking better therapies | Investors and entrepreneurs are beginning to bring new diagnostic tools to market that promise better results for cancer patients through the identification of mutations in cancer cells that can create more targeted therapies.
Earlier this ... |
| 13.12.2018 | Mission Bio Receives $30M Series B |
SOUTH SAN FRANCISCO, CA, Mission Bio, the pioneer in single-cell DNA analysis and precision genomics, today announced it raised $30 million in Series B funding.
>> Click here for more funding data on Mission Bio
>> To export... |
| 13.12.2018 | Genomic technology company Mission Bio raises $30M | The company will use the funding to expand its technology into CRISPR research
One of the most exciting prospects for healthtech is precision health, which encompasses the move toward tailored and personalized medicine vs a one-size-fits-al... |
| 13.12.2018 | Mission Bio Raises $30M in Series B Funding | Mission Bio, Inc., a South San Francisco, Calif.-based single-cell DNA analysis and precision genomics company, raised $30m in Series B funding.
Backers included Agilent Technologies (NYSE: A), Cota Capital, LAM Capital, and Mayfield.
The c... |
| 17.10.2017 | Term Sheet — Tuesday, October 17 | VCs + ICOs
Good morning, Term Sheet readers.
Paid Content How can you protect what you can't see? From ExtraHop
Today, my colleague Robert Hackett got his hands on some hard data that backs up some of these claims. Here are the highlights:
... |
| 17.10.2017 | Mission Bio Secures $10M in Series A Funding | Mission Bio, Inc., a South San Francisco, CA-based developer of single-cell DNA analysis, secured $10m in Series A funding.
The round was led by Mayfield Fund.
The company intends to use the funds to launch its Tapestri platform,
Led by Cha... |
| 07.02.2017 | Term Sheet — Tuesday, February 7 | SURVEY SAYS
Earlier this year I asked Term Sheet readers to take a confidence survey created by professional services provider Semaphore. More than 500 of you did (around 30% from the private equity, 26% from venture capital, with the rest ... |
| 06.02.2017 | Mission Bio Secures Seed Funding from Life Science Angels | Mission Bio, Inc., a South San Francisco, CA-based developer of a high throughput single-cell genomics system, secured a seed funding from angel investment group Life Science Angels (LSA).
The amount of the deal was not disclosed.
The compa... |
| - | Mission Bio raises $30M in Series B round to develop genomics platform | A company focused on DNA and genomics has raised its second major round of private investment.
South San Francisco, California-based Mission Bio said Thursday that it had raised $30 million in a Series B financing round, from Agilent Techno... |
